HK1147275A1 - 抗體 - Google Patents

抗體

Info

Publication number
HK1147275A1
HK1147275A1 HK11101502.6A HK11101502A HK1147275A1 HK 1147275 A1 HK1147275 A1 HK 1147275A1 HK 11101502 A HK11101502 A HK 11101502A HK 1147275 A1 HK1147275 A1 HK 1147275A1
Authority
HK
Hong Kong
Prior art keywords
axl
antibodies
axl antibodies
antibodies axl
Prior art date
Application number
HK11101502.6A
Other languages
English (en)
Inventor
‧海特曼
‧尼韋納
‧魯赫
‧沃特斯
‧澤勒
‧茨維克-瓦拉施
‧羅瑟
Original Assignee
製藥有限公司
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 製藥有限公司 filed Critical 製藥有限公司
Publication of HK1147275A1 publication Critical patent/HK1147275A1/zh

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2863—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/28—Compounds containing heavy metals
    • A61K31/282—Platinum compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
    • A61K31/7034—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
    • A61K31/704—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin attached to a condensed carbocyclic ring system, e.g. sennosides, thiocolchicosides, escin, daunorubicin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/75—Agonist effect on antigen
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Endocrinology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Reproductive Health (AREA)
  • Oncology (AREA)
  • Pulmonology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
HK11101502.6A 2007-11-12 2011-02-16 抗體 HK1147275A1 (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP07021931 2007-11-12
PCT/EP2008/009548 WO2009062690A1 (en) 2007-11-12 2008-11-12 Axl antibodies

Publications (1)

Publication Number Publication Date
HK1147275A1 true HK1147275A1 (zh) 2011-08-05

Family

ID=40280763

Family Applications (2)

Application Number Title Priority Date Filing Date
HK11101502.6A HK1147275A1 (zh) 2007-11-12 2011-02-16 抗體
HK13112909.0A HK1185622A1 (zh) 2007-11-12 2013-11-19 抗體

Family Applications After (1)

Application Number Title Priority Date Filing Date
HK13112909.0A HK1185622A1 (zh) 2007-11-12 2013-11-19 抗體

Country Status (20)

Country Link
US (1) US8933202B2 (zh)
EP (2) EP2918605A1 (zh)
JP (2) JP5769969B2 (zh)
KR (1) KR20100097684A (zh)
CN (2) CN103275227B (zh)
AU (1) AU2008323206B2 (zh)
BR (1) BRPI0820073A2 (zh)
CA (1) CA2705164A1 (zh)
CO (1) CO6280499A2 (zh)
DK (1) DK2220121T3 (zh)
ES (1) ES2556214T3 (zh)
HK (2) HK1147275A1 (zh)
IL (1) IL205607A0 (zh)
MX (1) MX2010005031A (zh)
MY (1) MY155621A (zh)
NZ (2) NZ599628A (zh)
RU (1) RU2506276C2 (zh)
SG (2) SG186000A1 (zh)
WO (1) WO2009062690A1 (zh)
ZA (1) ZA201003397B (zh)

Families Citing this family (49)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN103275227B (zh) 2007-11-12 2015-02-11 U3制药有限公司 Axl抗体
EP2853544A1 (en) 2007-11-15 2015-04-01 Chugai Seiyaku Kabushiki Kaisha Monoclonal antibody capable of binding to anexelekto, and use thereof
SI3702371T1 (sl) 2009-03-25 2023-01-31 Genentech, Inc. Protitelesa proti FGFR3 in postopki za uporabo le-teh
JP5909442B2 (ja) * 2009-05-11 2016-04-26 ユー３・ファーマ・ゲーエムベーハー ヒト化ａｘｌ抗体
EP2270053A1 (en) * 2009-05-11 2011-01-05 U3 Pharma GmbH Humanized AXL antibodies
MX2011012136A (es) 2009-05-15 2012-04-10 Chugai Pharmaceutical Co Ltd Anticuerpo anti-axl.
WO2011014457A1 (en) 2009-07-27 2011-02-03 Genentech, Inc. Combination treatments
US9005926B2 (en) 2009-10-02 2015-04-14 Biogen Idec Ma Inc. Methods of preventing and removing trisulfide bonds
KR20200100866A (ko) * 2010-01-22 2020-08-26 더 보드 어브 트러스티스 어브 더 리랜드 스탠포드 주니어 유니버시티 항-전이성 요법에서 ａｘｌ 신호전달의 저해
CN101858917B (zh) * 2010-06-02 2013-03-27 成都创宜生物科技有限公司 Axl单克隆抗体的应用及以Axl为检测指标的胎膜早破检测试剂盒和制备方法
MX336001B (es) 2010-06-18 2016-01-07 Genentech Inc Anticuerpos anti-axl y metodos de uso.
EP2670426B1 (en) 2011-01-31 2017-05-10 The General Hospital Corporation Multimodal trail molecules and uses in cellular therapies
EP3388443A1 (en) 2011-05-13 2018-10-17 Biogen MA Inc. Methods of preventing and removing trisulfide bonds
ES2677367T3 (es) 2011-06-22 2018-08-01 INSERM (Institut National de la Santé et de la Recherche Médicale) Anticuerpos anti-Axl y usos de los mismos
AU2012273954A1 (en) 2011-06-22 2014-01-09 Inserm (Institut National De La Sante Et De La Recherche Medicale) Anti-Axl antibodies and uses thereof
MX2014002289A (es) 2011-08-26 2015-03-20 Merrimack Pharmaceuticals Inc Anticuerpos fc especificos en tandem.
EP2589609A1 (en) * 2011-11-03 2013-05-08 Pierre Fabre Medicament Antigen binding protein and its use as addressing product for the treatment of cancer
US9862932B2 (en) 2012-07-24 2018-01-09 The General Hospital Corporation Oncolytic virus therapy for resistant tumors
US9605074B2 (en) * 2012-08-30 2017-03-28 The General Hospital Corporation Multifunctional nanobodies for treating cancer
US10669324B2 (en) 2012-10-30 2020-06-02 Suppremol Gmbh Vector encoding an Fc gamma receptor IIB protein and composition of the encoded protein
JP6195716B2 (ja) * 2013-02-15 2017-09-13 富士レビオ株式会社 抗癌剤耐性診断マーカー
AU2014225661A1 (en) 2013-03-06 2015-09-10 Merrimack Pharmaceuticals, Inc. Anti-c-Met tandem Fc bispecific antibodies
EP2837637A1 (en) 2013-08-16 2015-02-18 SuppreMol GmbH Novel anti-FcyRIIB IgG-type antibody
GB201410825D0 (en) 2014-06-18 2014-07-30 Bergenbio As Anti-axl antibodies
GB201410826D0 (en) * 2014-06-18 2014-07-30 Bergenbio As Anti-axl antibodies
US20170260261A1 (en) 2014-08-28 2017-09-14 Bioatla, Llc Conditionally Active Chimeric Antigen Receptors for Modified T-Cells
US10398774B2 (en) 2014-12-09 2019-09-03 INSERM (Institut National de la Santé et de la Recherche Médicale) Human monoclonal antibodies against AXL
CN116410318A (zh) * 2014-12-18 2023-07-11 卑尔根技术锻造股份公司 抗axl拮抗抗体
GB201506411D0 (en) 2015-04-15 2015-05-27 Bergenbio As Humanized anti-axl antibodies
EP3297662A4 (en) * 2015-05-18 2019-03-13 Agensys, Inc. ANTIBODY BINDING TO AXL PROTEINS
WO2016187356A1 (en) * 2015-05-18 2016-11-24 Agensys, Inc. Antibodies that bind to axl proteins
GB201509338D0 (en) 2015-05-29 2015-07-15 Bergenbio As Combination therapy
SI3319993T1 (sl) * 2015-07-10 2020-06-30 Genmab A/S AXL-specifični konjugati zdravila s protitelesom za zdravljenje raka
CN109563164A (zh) 2016-04-15 2019-04-02 生物蛋白有限公司 抗axl抗体、抗体片段和它们的免疫缀合物以及其用途
HRP20221298T1 (hr) 2016-05-13 2022-12-23 Bioatla, Inc. Anti-ror2 protutijela, fragmenti protutijela, njihovi imunokonjugati i njihove uporabe
GB201610902D0 (en) * 2016-06-22 2016-08-03 Bergen Teknologioverforing As And Bergenbio As Anti-Axl Antagonistic Antibodies
MX2019008503A (es) 2017-01-18 2019-09-13 F1 Oncology Inc Receptores de antigenos quimericos contra axl o ror2 y metodos de uso de los mismos.
US20200129637A1 (en) 2017-04-20 2020-04-30 Adc Therapeutics Sa Combination therapy with an anti-axl antibody-drug conjugate
CN110540592B (zh) * 2018-05-29 2022-08-09 杭州尚健生物技术有限公司 结合axl蛋白的抗体及其应用
CN109160941B (zh) * 2018-09-29 2020-09-04 未名生物医药有限公司 蛋白序列17e11及其用途
GB201912059D0 (en) 2019-08-22 2019-10-09 Bergenbio As Combaination therapy of a patient subgroup
EP4087657A1 (en) 2020-01-08 2022-11-16 Synthis Therapeutics, Inc. Alk5 inhibitor conjugates and uses thereof
GB202004189D0 (en) 2020-03-23 2020-05-06 Bergenbio As Combination therapy
WO2021204713A1 (en) 2020-04-08 2021-10-14 Bergenbio Asa Axl inhibitors for antiviral therapy
GB202006072D0 (en) 2020-04-24 2020-06-10 Bergenbio Asa Method of selecting patients for treatment with cmbination therapy
GB202104037D0 (en) 2021-03-23 2021-05-05 Bergenbio Asa Combination therapy
EP4357365A1 (en) * 2021-06-16 2024-04-24 Shanghai Sinobay Biotechnology Co., Ltd. Antibody targeting axl protein and antigen binding fragment thereof, and preparation method therefor and application thereof
CN116348497B (zh) * 2023-01-05 2023-11-17 浙江时迈药业有限公司 针对axl的抗体及其用途
CN116715774B (zh) * 2023-05-12 2023-11-24 武汉爱博泰克生物科技有限公司 针对人axl的兔单克隆抗体及其制备方法和应用

Family Cites Families (70)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3180193A (en) 1963-02-25 1965-04-27 Benedict David Machines for cutting lengths of strip material
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US4931385A (en) * 1985-06-24 1990-06-05 Hygeia Sciences, Incorporated Enzyme immunoassays and immunologic reagents
GB8607679D0 (en) 1986-03-27 1986-04-30 Winter G P Recombinant dna product
EP0623679B1 (en) 1987-05-21 2003-06-25 Micromet AG Targeted multifunctional proteins
US5750172A (en) 1987-06-23 1998-05-12 Pharming B.V. Transgenic non human mammal milk
AU631545B2 (en) 1988-04-15 1992-12-03 Protein Design Labs, Inc. Il-2 receptor-specific chimeric antibodies
GB8823869D0 (en) 1988-10-12 1988-11-16 Medical Res Council Production of antibodies
US5175384A (en) 1988-12-05 1992-12-29 Genpharm International Transgenic mice depleted in mature t-cells and methods for making transgenic mice
IL162181A (en) 1988-12-28 2006-04-10 Pdl Biopharma Inc A method of producing humanized immunoglubulin, and polynucleotides encoding the same
DE3900534A1 (de) * 1989-01-10 1990-07-12 Boehringer Mannheim Gmbh Diagnostischer nachweis unter verwendung von chimaeren antikoerpern
US5633076A (en) 1989-12-01 1997-05-27 Pharming Bv Method of producing a transgenic bovine or transgenic bovine embryo
US6150584A (en) 1990-01-12 2000-11-21 Abgenix, Inc. Human antibodies derived from immunized xenomice
US6075181A (en) 1990-01-12 2000-06-13 Abgenix, Inc. Human antibodies derived from immunized xenomice
DE69133566T2 (de) 1990-01-12 2007-12-06 Amgen Fremont Inc. Bildung von xenogenen Antikörpern
US6673986B1 (en) 1990-01-12 2004-01-06 Abgenix, Inc. Generation of xenogeneic antibodies
FR2664073A1 (fr) 1990-06-29 1992-01-03 Thomson Csf Moyens de marquage d'objets, procede de realisation et dispositif de lecture.
GB9014932D0 (en) 1990-07-05 1990-08-22 Celltech Ltd Recombinant dna product and method
KR100272077B1 (ko) 1990-08-29 2000-11-15 젠팜인터내셔날,인코포레이티드 이종 항체를 생산할 수 있는 전이유전자를 가진 인간이외의 동물
US5814318A (en) 1990-08-29 1998-09-29 Genpharm International Inc. Transgenic non-human animals for producing heterologous antibodies
DE69133557D1 (de) 1990-08-29 2007-03-15 Pharming Intellectual Pty Bv Homologe rekombination in säugetier-zellen
US5625126A (en) 1990-08-29 1997-04-29 Genpharm International, Inc. Transgenic non-human animals for producing heterologous antibodies
US5874299A (en) 1990-08-29 1999-02-23 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
US5633425A (en) 1990-08-29 1997-05-27 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
US5770429A (en) 1990-08-29 1998-06-23 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
US6300129B1 (en) 1990-08-29 2001-10-09 Genpharm International Transgenic non-human animals for producing heterologous antibodies
US5877397A (en) 1990-08-29 1999-03-02 Genpharm International Inc. Transgenic non-human animals capable of producing heterologous antibodies of various isotypes
US5661016A (en) 1990-08-29 1997-08-26 Genpharm International Inc. Transgenic non-human animals capable of producing heterologous antibodies of various isotypes
US5545806A (en) 1990-08-29 1996-08-13 Genpharm International, Inc. Ransgenic non-human animals for producing heterologous antibodies
US5789650A (en) 1990-08-29 1998-08-04 Genpharm International, Inc. Transgenic non-human animals for producing heterologous antibodies
US6255458B1 (en) 1990-08-29 2001-07-03 Genpharm International High affinity human antibodies and human antibodies against digoxin
WO1992022670A1 (en) 1991-06-12 1992-12-23 Genpharm International, Inc. Early detection of transgenic embryos
AU2235992A (en) 1991-06-14 1993-01-12 Genpharm International, Inc. Transgenic immunodeficient non-human animals
WO1994004679A1 (en) 1991-06-14 1994-03-03 Genentech, Inc. Method for making humanized antibodies
US5468634A (en) * 1991-06-24 1995-11-21 The University Of North Carolina At Chapel Hill Axl oncogene
WO1993004169A1 (en) 1991-08-20 1993-03-04 Genpharm International, Inc. Gene targeting in animal cells using isogenic dna constructs
JPH05244982A (ja) 1991-12-06 1993-09-24 Sumitomo Chem Co Ltd 擬人化ｂ−ｂ１０
CA2124967C (en) 1991-12-17 2008-04-08 Nils Lonberg Transgenic non-human animals capable of producing heterologous antibodies
NZ253943A (en) 1992-06-18 1997-01-29 Genpharm Int Transfering polynucleotides into eukaryotic cells using co-lipofection complexes of a cationic lipid and the polynucleotide
JPH07509137A (ja) 1992-07-24 1995-10-12 セル　ジェネシス，インク． 異種抗体の生産
US5981175A (en) 1993-01-07 1999-11-09 Genpharm Internation, Inc. Methods for producing recombinant mammalian cells harboring a yeast artificial chromosome
PT804070E (pt) 1993-03-09 2000-11-30 Genzyme Corp Isolamento de componentes de interesse a partir do leite.
EP0754225A4 (en) 1993-04-26 2001-01-31 Genpharm Int HETEROLOGIC ANTIBODY-PRODUCING TRANSGENIC NON-HUMAN ANIMALS
US5625825A (en) 1993-10-21 1997-04-29 Lsi Logic Corporation Random number generating apparatus for an interface unit of a carrier sense with multiple access and collision detect (CSMA/CD) ethernet data network
US5827690A (en) 1993-12-20 1998-10-27 Genzyme Transgenics Corporatiion Transgenic production of antibodies in milk
US5643763A (en) 1994-11-04 1997-07-01 Genpharm International, Inc. Method for making recombinant yeast artificial chromosomes by minimizing diploid doubling during mating
KR20050085971A (ko) 1995-04-27 2005-08-29 아브게닉스, 인크. 면역화된 제노마우스 유래의 인간 항체
AU2466895A (en) 1995-04-28 1996-11-18 Abgenix, Inc. Human antibodies derived from immunized xenomice
WO1997007671A1 (fr) 1995-08-29 1997-03-06 Kirin Beer Kabushiki Kaisha Animal chimerique et procede de constitution
US6730300B2 (en) * 1996-03-20 2004-05-04 Immunomedics, Inc. Humanization of an anti-carcinoembryonic antigen anti-idiotype antibody and use as a tumor vaccine and for targeting applications
JPH1084958A (ja) * 1996-09-17 1998-04-07 Pola Chem Ind Inc 抗繊維芽細胞増殖因子６モノクローナル抗体
EP2314625B1 (en) 1996-12-03 2014-05-07 Amgen Fremont Inc. Transgenic mammals having human Ig loci including plural VH and Vkappa regions and antibodies produced therefrom
CA2341029A1 (en) 1998-08-17 2000-02-24 Abgenix, Inc. Generation of modified molecules with increased serum half-lives
CA2376192A1 (en) 1999-06-07 2000-12-14 Neorx Corporation Streptavidin expressed gene fusions and methods of use thereof
US6833268B1 (en) 1999-06-10 2004-12-21 Abgenix, Inc. Transgenic animals for producing specific isotypes of human antibodies via non-cognate switch regions
EP1382969A1 (en) * 2002-07-17 2004-01-21 Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. Diagnosis and prevention of cancer cell invasion
HN2004000285A (es) * 2003-08-04 2006-04-27 Pfizer Prod Inc ANTICUERPOS DIRIGIDOS A c-MET
EP1697415A1 (en) * 2003-11-12 2006-09-06 Biogen Idec MA Inc. NEONATAL Fc RECEPTOR (FcRn)-BINDING POLYPEPTIDE VARIANTS, DIMERIC Fc BINDING PROTEINS AND METHODS RELATED THERETO
JP2008520186A (ja) 2004-10-01 2008-06-19 マックス−プランク−ゲゼルシャフト・ツア・フェルデルング・デア・ヴィッセンシャフテン・エー・ファオ 哺乳類ｅａｇ１イオンチャネルタンパク質に対する新規の抗体
ATE541859T1 (de) * 2005-01-27 2012-02-15 Novimmune Sa Humane anti-interferon-gamma-antikörper und verfahren zu ihrer verwendung
WO2006096490A2 (en) * 2005-03-08 2006-09-14 Pharmacia & Upjohn Company Llc ANTI-MAdCAM ANTIBODY COMPOSITIONS
US20110123440A1 (en) 2005-03-29 2011-05-26 Genevieve Hansen Altered Antibody FC Regions and Uses Thereof
DK2390267T3 (da) 2005-06-07 2013-08-26 Esbatech A Novartis Co Llc Stabile og opløselige antistoffer, der hæmmer TNF(alfa)
UA94060C2 (ru) * 2005-09-07 2011-04-11 Эмджен Фримонт Инк. Моноклональное антитело, которое специфически связывает alk-1
WO2007032634A1 (en) * 2005-09-12 2007-03-22 Industry Foundation Of Chonnam National University A method for production of mature natural killer cell
US20090087431A1 (en) * 2007-07-02 2009-04-02 Wyeth Methods of treating bone disorders with modulators of axl
CA2703519C (en) * 2007-11-09 2017-04-18 The Salk Institute For Biological Studies Use of tam receptor inhibitors as immunoenhancers and tam activators as immunosuppressors
CN103275227B (zh) 2007-11-12 2015-02-11 U3制药有限公司 Axl抗体
JP6071725B2 (ja) 2013-04-23 2017-02-01 カルソニックカンセイ株式会社 電気自動車の駆動力制御装置
US11284893B2 (en) 2019-04-02 2022-03-29 Covidien Lp Stapling device with articulating tool assembly

Also Published As

Publication number Publication date
US20100330095A1 (en) 2010-12-30
JP2011505120A (ja) 2011-02-24
CN103275227B (zh) 2015-02-11
IL205607A0 (en) 2010-11-30
JP2015221804A (ja) 2015-12-10
MY155621A (en) 2015-11-13
SG10201405835TA (en) 2014-10-30
KR20100097684A (ko) 2010-09-03
MX2010005031A (es) 2010-06-25
BRPI0820073A2 (pt) 2015-06-23
EP2220121A1 (en) 2010-08-25
JP5769969B2 (ja) 2015-08-26
EP2220121B1 (en) 2015-08-19
RU2010123888A (ru) 2011-12-20
CA2705164A1 (en) 2009-05-22
NZ585465A (en) 2012-12-21
ES2556214T3 (es) 2016-01-14
EP2918605A1 (en) 2015-09-16
WO2009062690A1 (en) 2009-05-22
CO6280499A2 (es) 2011-05-20
CN101939336B (zh) 2014-05-14
CN103275227A (zh) 2013-09-04
CN101939336A (zh) 2011-01-05
ZA201003397B (en) 2011-04-28
DK2220121T3 (en) 2015-12-07
HK1185622A1 (zh) 2014-02-21
NZ599628A (en) 2013-11-29
US8933202B2 (en) 2015-01-13
SG186000A1 (en) 2012-12-28
AU2008323206A1 (en) 2009-05-22
AU2008323206B2 (en) 2014-08-14
RU2506276C2 (ru) 2014-02-10

Similar Documents

Publication Publication Date Title
HK1185622A1 (zh) 抗體
GB0708002D0 (en) Antibodies
HK1136970A1 (zh) 五特異性抗體
EP2138576A4 (en) ANTI-CLAUDIN-4 ANTIBODY
SI2200700T1 (sl) Nova protitelesa
EP2241578A4 (en) ANTI-CLDN6 ANTIBODIES
EP2163467A4 (en) VEHICLE
GB0821100D0 (en) Antibodies
ZA200905598B (en) Vehicle
EP2128012A4 (en) VEHICLE
EP2177425A4 (en) VEHICLE
EP2172483A4 (en) ANTI-MUC17 ANTIBODY
GB2448914B (en) Vehicle
EP2337798A4 (en) BSA-SPECIFIC ANTIBODIES
GB0718737D0 (en) Antibodies
IL205073A0 (en) Anti-bst2 antibody
GB0702888D0 (en) Novel Antibodies
ZA201006099B (en) Anti-tyrp1 antibodies
ZA201007976B (en) Anti-pirb antibodies
GB0818356D0 (en) Antibodies
EP2194815A4 (en) BED-VEHICLE BED
GB0701067D0 (en) Improved vehicles
GB0911770D0 (en) Antibody
GB2446009B (en) Improved vehicles
GB0724185D0 (en) Antibodies

Legal Events

Date Code Title Description
PC Patent ceased (i.e. patent has lapsed due to the failure to pay the renewal fee)

Effective date: 20181117